Tandem Diabetes Care (BSP:T2ND34) Cyclically Adjusted Revenue per Share: R$0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:T2ND34 Tandem Diabetes Care Inc BSP:T2ND34
45 GF Score
Price R$5.80
GF Value R$9.93
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Cyclically Adjusted Revenue per Share?

Tandem Diabetes Care BSP:T2ND34 -6.15% 45 Cyclically Adjusted Revenue per Share is R$0.00 as of Mar. 2026. GuruFocus rates BSP:T2ND34 with a GF Score™ of 45/100 and a GF Value™ of R$9.93 (Possible Value Trap). The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Tandem Diabetes Care's adjusted revenue per share for the three months ended in Mar. 2026 was R$18.902. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Tandem Diabetes Care's average Cyclically Adjusted Revenue Growth Rate was -9.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Tandem Diabetes Care was -5.30% per year. The lowest was -5.30% per year. And the median was -5.30% per year.

As of today (2026-07-27), Tandem Diabetes Care's current stock price is R$5.80. Tandem Diabetes Care's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was R$0.00. Tandem Diabetes Care's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tandem Diabetes Care was 6.99. The lowest was 0.65. And the median was 1.63.


Tandem Diabetes Care  (BSP:T2ND34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tandem Diabetes Care was 6.99. The lowest was 0.65. And the median was 1.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Tandem Diabetes Care Cyclically Adjusted Revenue per Share Related Terms


Tandem Diabetes Care Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Cyclically Adjusted Revenue per Share Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tandem Diabetes Care Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BSP:T2ND34 vs AVNS, IRMD, AORT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Cyclically Adjusted PS Ratio falls into.


BSP:T2ND34
45GF Score
Tandem Diabetes Care Inc BSP:T2ND34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tandem Diabetes Care's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=18.902/330.2130*330.2130
=18.902

Current CPI (Mar. 2026) = 330.2130.

Tandem Diabetes Care Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 25.807 241.018 35.358
201609 13.056 241.428 17.857
201612 31.413 241.432 42.964
201703 18.611 243.801 25.207
201706 14.045 244.955 18.933
201709 16.298 246.819 21.805
201712 13.121 246.524 17.575
201803 4.971 249.554 6.578
201806 2.526 251.989 3.310
201809 3.418 252.439 4.471
201812 5.143 251.233 6.760
201903 4.387 254.202 5.699
201906 6.176 256.143 7.962
201909 6.587 256.759 8.471
201912 7.512 256.974 9.653
202003 8.009 258.115 10.246
202006 9.380 257.797 12.015
202009 10.848 260.280 13.763
202012 13.889 260.474 17.608
202103 12.727 264.877 15.866
202106 13.182 271.696 16.021
202109 14.637 274.310 17.620
202112 18.325 278.802 21.704
202203 13.704 287.504 15.740
202206 15.775 296.311 17.580
202209 16.697 296.808 18.576
202212 17.964 296.797 19.987
202303 13.668 301.836 14.953
202306 14.668 305.109 15.875
202309 14.078 307.789 15.104
202312 14.750 306.746 15.878
202403 14.611 312.332 15.447
202406 18.390 314.175 19.329
202409 20.615 315.301 21.590
202412 26.150 315.605 27.360
202503 20.327 319.799 20.989
202506 19.907 322.561 20.379
202509 19.759 324.800 20.088
202512 23.291 324.054 23.734
202603 18.902 330.213 18.902

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$0.00 mean?
Tandem Diabetes Care (BSP:T2ND34) has a Cyclically Adjusted Revenue per Share of R$0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Cyclically Adjusted Revenue per Share too high?
Tandem Diabetes Care's current Cyclically Adjusted Revenue per Share is R$0.00. Overall, Tandem Diabetes Care has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Cyclically Adjusted Revenue per Share compare to AVNS and IRMD?
Tandem Diabetes Care's Cyclically Adjusted Revenue per Share of R$0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Cyclically Adjusted Revenue per Share is R$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (BSP:T2ND34) is currently considered Possible Value Trap. The stock's GF Value™ is R$9.93, compared to a current price of R$5.80 — trading 41.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$0.00. Tandem Diabetes Care's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Tandem Diabetes Care (BSP:T2ND34), the current Cyclically Adjusted Revenue per Share is R$0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (BSP:T2ND34) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of R$5.80 is trading 41.6% below its estimated GF Value™ of R$9.93. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for BSP:T2ND34:

  • Cyclically Adjusted Revenue per Share: R$0.00
  • GF Value™: R$9.93 vs. price of R$5.80 (41.6% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the BSP:T2ND34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tandem Diabetes Care Business Description

Other Exchanges TNDM:USA0M0F:UKTD5A:Germany
Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
45GF Score

Get the complete analysis for BSP:T2ND34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$5.80
Price
R$9.93
GF Value